Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 8/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | HPGD | P15428 | 5/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TTR | P02766 | 2/20 | 0.39 |
| ▸ | PGR | P06401 | 2/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29768378 | 1.00 | TSHR (0.56) | TSHRHSD17B10ALDH1A1HPGDCYP3A4 | |
| SCHEMBL950545 | 0.83 | ALDH1A1 (0.56) | TSHRHSD17B10ALDH1A1HPGDCYP3A4 | |
| SCHEMBL30973045 | 0.75 | ALDH1A1 (0.41) | TSHRHSD17B10ALDH1A1HPGDCYP3A4 | |
| SCHEMBL25085872 | 0.75 | ALDH1A1 (0.41) | TSHRHSD17B10ALDH1A1HPGDCYP3A4 | |
| SCHEMBL31200564 | 0.75 | SELL (0.46) | TSHRHSD17B10ALDH1A1HPGDCYP3A4 | |
| SCHEMBL25085814 | 0.75 | TSHR (0.41) | TSHRHSD17B10ALDH1A1HPGDCYP3A4 | |
| SCHEMBL23883715 | 0.75 | TSHR (0.41) | TSHRHSD17B10ALDH1A1HPGDCYP3A4 | |
| SCHEMBL30412164 | 0.75 | CA9 (0.36) | TSHRHSD17B10ALDH1A1HPGDCYP3A4 | |
| SCHEMBL29375263 | 0.72 | HSD17B10 (1.00) | TSHRHSD17B10ALDH1A1HPGDCYP3A4 | |
| SCHEMBL70194 | 0.72 | HSD17B10 (0.72) | TSHRHSD17B10ALDH1A1HPGDCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113603573-A | Preparation process of 3, 5-dichloro-2-iodoanisole | 苏州求索生物科技有限公司 | 2021-11-05 | — | — | CN | claimed |
| EP-4680601-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | Sanofi (FR) | 2026-01-21 | — | — | EP | disclosed |
| EP-4656635-A1 | SUBSTITUTED BENZENE COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2025-12-03 | — | — | EP | disclosed |
| US-20250270188-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2025-08-28 | — | — | US | disclosed |
| US-20250115558-A1 | PYRIDAZINE DERIVATIVES AND RELATED USES | NODTHERA LTD (GB) | 2025-04-10 | — | — | US | disclosed |
| US-20240424113-A1 | CONJUGATES COMPRISING ANTIFUNGALS AND HEAT SHOCK PROTEIN 90 (HSP90) INHIBITORS AND METHODS OF USE THEREOF | BRIGHT ANGEL THERAPEUTICS INC. (CA) | 2024-12-26 | — | — | US | disclosed |
| US-12139471-B2 | NLRP3 inflammasome inhibitors | NOVARTIS AG (CH) | 2024-11-12 | — | — | US | disclosed |
| US-20240360151-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | SANOFI (FR) | 2024-10-31 | — | — | US | disclosed |
| WO-2024188994-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | SANOFI (FR) | 2024-09-19 | — | — | WO | disclosed |
| EP-4419531-A1 | CONJUGATES COMPRISING ANTIFUNGALS AND HEAT SHOCK PROTEIN 90 (HSP90) INHIBITORS AND METHODS OF USE THEREOF | Bright Angel Therapeutics Inc. (CA) | 2024-08-28 | — | — | EP | disclosed |
| US-20100093696-A1 | 2-AMINO PYRIMIDINE COMPOUNDS | PFIZER INC. | 2010-04-15 | — | — | US | disclosed |
| US-20100093696-A1 | 2-AMINO PYRIMIDINE COMPOUNDS | PFIZER INC. | 2010-04-15 | — | — | US | disclosed |
| US-20100093696-A1 | 2-AMINO PYRIMIDINE COMPOUNDS | PFIZER INC. | 2010-04-15 | — | — | US | disclosed |
| WO-2010018481-A1 | 2-AMINO PYRIMIDINE COMPOUNDS AS POTENT HSP-90 INHIBITORS | PFIZER INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041681-A1 | 2-AMINO PYRIMIDINE COMPOUNDS AS POTENT HSP-90 INHIBITORS | PFIZER INC | 2010-02-18 | — | — | US | disclosed |
| US-20100041681-A1 | 2-AMINO PYRIMIDINE COMPOUNDS AS POTENT HSP-90 INHIBITORS | PFIZER INC | 2010-02-18 | — | — | US | disclosed |
| EP-2118111-A1 | 2-AMIN0-5, 7-DIHYDR0-6H- PYRROLO [3, 4-D] PYRIMIDINE DERIVATIVES AS HSP-90 INHIBITORS FOR TREATING CANCER | Pfizer Inc. (US) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008096218-A1 | 2-AMIN0-5, 7-DIHYDR0-6H- PYRROLO [3, 4-D] PYRIMIDINE DERIVATIVES AS HSP-90 INHIBITORS FOR TREATING CANCER | PFIZER INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008096218-A1 | 2-AMIN0-5, 7-DIHYDR0-6H- PYRROLO [3, 4-D] PYRIMIDINE DERIVATIVES AS HSP-90 INHIBITORS FOR TREATING CANCER | PFIZER INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008059368-A2 | FUSED 2-AMINO PYRIMIDINE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | PFIZER PRODUCTS INC. (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360151-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | NLRP3, NOD1, NLRP1 | TSHR 1264/4885HSD17B10 2591/4885ALDH1A1 3601/4885 |
| US-20100041681-A1 | 2-AMINO PYRIMIDINE COMPOUNDS AS POTENT HSP-90 INHIBITORS | HSP90AB2P, HSP90AB1, HSP90AA1 | TSHR 4713/4885HSD17B10 2909/4885ALDH1A1 1084/4885 |
| US-20250115558-A1 | PYRIDAZINE DERIVATIVES AND RELATED USES | IL1B, NLRP3, NOD1 | TSHR 4105/4885HSD17B10 3078/4885ALDH1A1 476/4885 |
| US-20100093696-A1 | 2-AMINO PYRIMIDINE COMPOUNDS | HSP90AB2P, HSP90AB1, HSP90AA1 | TSHR 4610/4885HSD17B10 2668/4885ALDH1A1 771/4885 |
| US-20240424113-A1 | CONJUGATES COMPRISING ANTIFUNGALS AND HEAT SHOCK PROTEIN 90 (HSP90) INHIBITORS AND METHODS OF USE THEREOF | HSP90AB1, HSP90B1, HSP90AA1 | TSHR 4445/4885HSD17B10 976/4885ALDH1A1 596/4885 |
| US-12139471-B2 | NLRP3 inflammasome inhibitors | NLRP3, NLRP1, NOD1 | TSHR 2465/4885HSD17B10 3067/4885ALDH1A1 2869/4885 |
| US-20250270188-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | TSHR 2465/4885HSD17B10 3067/4885ALDH1A1 2869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.